PEAK6
REGN icon

PEAK6’s Regeneron Pharmaceuticals REGN Stock Holding History

PEAK6’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Sell
3,600
-2,500
-41% -$1.7M ﹤0.01% 1267
2026
Q1 		$4.71M Sell
6,100
-33,300
-85% -$25.5M 0.01% 926
2025
Q4 		$30.4M Sell
39,400
-2,700
-6% -$1.83M 0.06% 274
2025
Q3 		$23.7M Sell
42,100
-16,000
-28% -$9.05M 0.03% 372
2025
Q2 		$30.5M Buy
58,100
+47,900
+470% +$26.7M 0.06% 277
2025
Q1 		$6.47M Buy
10,200
+6,700
+191% +$4.61M 0.01% 773
2024
Q4 		$2.49M Buy
+3,500
New +$2.94M 0.01% 1291

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PEAK6's REGN Position: Q2 2026 in Review

PEAK6 reduced its Regeneron Pharmaceuticals (REGN) stake by 88% in Q2 2026, selling an estimated $1.77M and leaving 355 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

PEAK6 first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.5M in Q2 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • PEAK6 held 355 shares of Regeneron Pharmaceuticals worth $221K as of Q2 2026.
  • PEAK6 sold 2,600 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.77M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2247 holding.
  • PEAK6 first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • PEAK6's Regeneron Pharmaceuticals position peaked at $19.5M in Q2 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.